Back to Journals » Drug Design, Development and Therapy » Volume 13

Can a cyclooxygenase inhibitor be an option for treatment of ovarian hyperstimulation syndrome?

Authors Çilgin H

Received 24 September 2018

Accepted for publication 25 February 2019

Published 5 April 2019 Volume 2019:13 Pages 1099—1105

DOI https://doi.org/10.2147/DDDT.S188583

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Palas Chanda

Peer reviewer comments 3

Editor who approved publication: Prof. Dr. Cristiana Tanase


Hasan Çilgin

Medicine Faculty, Obstetrics and Gynecology Department, Kafkas University, Kars, Turkey

Purpose: This study aimed to investigate the role of a cyclooxygenase inhibitor in ovarian hyperstimulation syndrome (OHSS) treatment and compare it with cabergoline.
Materials and methods: A total of 32 immature female Wistar albino rats were randomly divided into four groups, with each group consisting of eight rats. The first group received only saline for 6 consecutive days, and the remaining 24 rats were given 10 IU of recombinant follicle stimulating hormone subcutaneously on 5 consecutive days. On day 6, 30 IU of human chorionic gonadotropin was administered for OHSS induction. After the development of OHSS, while the second group had no further intervention, the third and fourth groups were given cabergoline and celecoxib daily for 6 days, respectively. Besides weight and hematocrit values, vascular endothelial growth factor (VEGF), IL-2, and endothelin-1 (ET-1) levels were evaluated.
Results: Initially, no significant differences were observed between the groups with respect to the evaluated parameters. Although there were no differences between the weight and hematocrit values at the end of treatment (P=0.158, P=0.674), the difference between group 1 and the other groups was statistically significant after OHSS was established (P=0.001, P=0.004). Comparison of the groups in terms of VEGF, ET-1, and IL-2 levels revealed that the difference between group 1 and the other groups was significant after OHSS was formed (P=0.012, P=0.018, P=0.015). After treatment, however, a significant difference was observed only between group 2 and the other groups (P=0.001, P=0.002, P=0.038).
Conclusion: According to these results, celecoxib significantly decreased VEGF, IL-2, and ET-1 levels as much as cabergoline and could reduce the extent of OHSS development.

Keywords: cabergoline, celecoxib, cyclooxygenase type 2, endothelin-1, IL-2, ovarian hyperstimulation syndrome
 

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]